Spring Bank Pharmaceuticals signs NIH research agreement
Photo | Google
Spring Bank Pharmaceuticals' headquarters in Hopkinton
Spring Bank Pharmaceuticals of Hopkinton has signed a research agreement with a subsidiary of the National Institutes of Health to evaluate its hepatitis B treatment.
Spring Bank's agreement with the National Institute of Allergy and Infectious Diseases includes a non-clinical evaluation agreement for the firm to access the institute's pre-clinical services program to evaluate therapy, known as antisense oligonucleotide compounds.
The clinical-stage biopharmaceutical company says a significant unmet need remains for therapies to help with hepatitis B, also known as HBV, a potentially life-threatening liver infection. It hopes to use its therapy in clinical trials in late 2020.
Spring Bank has been moving ahead this summer on another drug. It has been accepted by the U.S. Food and Drug Administration to begin clinical trials on an intravenously administered medicine aimed to treat some forms of lung, colorectal and skin cancers. Results for those trials are expected in the middle of next year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments